America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What types of cancer does AOH1996 show promise in treating?
**Interview with Dr. Linda Malkas, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope Hospital**
**Editor**: Thank you for joining us today, Dr. Malkas. You’ve been instrumental in the development of a new cancer drug known as AOH1996. Can you explain how this drug works and what makes it different from traditional chemotherapy?
**Dr. Malkas**: Thank you for having me. AOH1996 is a groundbreaking drug that employs a targeted approach to chemotherapy. Imagine an airline hub being shut down to stop the flow of planes—our drug does something similar by specifically targeting cancer cells while leaving healthy cells unharmed. The molecule attacks a mutated form of a protein called PCNA, which is critical for DNA replication and tumor growth.
**Editor**: That’s fascinating. You mentioned the drug has been effective on various cancer types. Can you elaborate on the types of cancer AOH1996 targets?
**Dr. Malkas**: Absolutely. In our studies, AOH1996 has shown promise in treating several aggressive cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Its ability to selectively kill cancer cells by disrupting their reproductive cycle is what makes it truly revolutionary.
**Editor**: Your recent study was published in ‘Cell Chemical Biology’. What were the key findings from your research?
**Dr. Malkas**: We tested AOH1996 on over 70 cancer cell lines, and the results were remarkable. The drug selectively killed cancer cells, effectively disrupting their normal cell cycle without adversely affecting healthy cells. This indicates a much more targeted therapy that could reduce side effects typically associated with conventional chemotherapy.
**Editor**: What are the next steps for AOH1996?
**Dr. Malkas**: The next step is to advance our findings into clinical trials involving human subjects. We are incredibly excited about the potential of AOH1996 and believe it could bring new hope to patients battling these challenging cancers.
**Editor**: Thank you, Dr. Malkas, for sharing your insights. We look forward to seeing the results from the upcoming clinical trials.
**Dr. Malkas**: Thank you for spotlighting this important research. We are hopeful for the future of cancer treatment.